Compare FND & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FND | INAB |
|---|---|---|
| Founded | 2000 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | RETAIL: Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 10.6M |
| IPO Year | 2017 | 2021 |
| Metric | FND | INAB |
|---|---|---|
| Price | $61.53 | $2.24 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 2 |
| Target Price | $82.59 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 2.4M | 675.8K |
| Earning Date | 02-19-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.08 | N/A |
| EPS | ★ 2.00 | N/A |
| Revenue | ★ $4,661,833,000.00 | N/A |
| Revenue This Year | $6.22 | N/A |
| Revenue Next Year | $7.82 | N/A |
| P/E Ratio | $30.98 | ★ N/A |
| Revenue Growth | ★ 6.04 | N/A |
| 52 Week Low | $55.11 | $1.17 |
| 52 Week High | $108.76 | $12.53 |
| Indicator | FND | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 45.49 | 64.84 |
| Support Level | $60.38 | $1.17 |
| Resistance Level | $63.82 | $2.24 |
| Average True Range (ATR) | 1.97 | 0.24 |
| MACD | 0.11 | 0.08 |
| Stochastic Oscillator | 31.67 | 98.10 |
Floor & Decor Holdings Inc operates as a specialty retailer in the hard surface flooring market. Its stores offer a range of tile, wood, laminate, and natural stone flooring products, as well as decorative and installation accessories at everyday low prices. It appeals to a variety of customers including professional installers, commercial businesses, Do It Yourself (DIY) customers, and customers who buy the products for professional installation. Geographically, the group has a presence in the United States region and also offers its product through an e-commerce site.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.